December 17, 2019
Meiji Seika Pharma said on December 16 that it has started a PI clinical study in Europe for DMB-3115, a biosimilar version of Stelara (ustekinumab), together with South Korea’s Dong-A Socio Holdings. The first patient was dosed on December 13...read more